“Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study” Vasilios Tzilas, Argyris Tzouvelekis, Evangelos Bouros, Theodoros Karampitsakos, Maria Ntassiou, Eleni Avdoula, Athena Trachalaki, Katerina Antoniou, Ganesh Raghu and Demosthenes Bouros. ERJ Open Res 2020; 6: 00152-2020.

This article was originally published with an error in figure 1. The corrected figure is shown below, and the article has been corrected and republished online.

FIGURE 1.

Flowchart of the study. Multidisciplinary team discussion (MDD) was performed by two pulmonologists experienced in interstitial lung disease (ILDs), a thoracic radiologist and a pathologist in cases with available lung biopsy. There was one patient with a usual interstitial pneumonia (UIP) pattern (and bronchoalveolar lavage (BAL) lymphocytosis >20%), five patients with possible UIP pattern (n=3 with BAL lymphocytosis >20%) and 24 patients with mosaic attenuation, most (n=16) with “head and cheese sign” (n=6 with BAL lymphocytosis >20%). IPF: idiopathic pulmonary fibrosis; HP: hypersensitivity pneumonitis.